Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571483 | 1.00 | CYP3A4 (0.59) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL27631295 | 0.84 | CYP3A4 (0.68) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5274419 | 0.84 | CYP3A4 (0.60) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL15899627 | 0.81 | ABCG2 (0.54) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3898402 | 0.80 | ABCB1 (0.57) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5072293 | 0.80 | MGAM (0.74) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL28343536 | 0.79 | CYP3A4 (0.58) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL28252602 | 0.79 | CYP3A4 (0.60) | CYP3A4MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2052448 | 0.78 | IKBKB (0.58) | CYP3A4KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL7047705 | 0.78 | CYP3A4 (0.59) | CYP3A4MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114796194-A | Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor | 澳门大学 | 2022-07-29 | — | — | CN | claimed |
| CN-110872267-A | Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor | 复旦大学 | 2020-03-10 | — | — | CN | claimed |
| CN-114796194-B | Application of DA adducts derived from Morus plants | 澳门大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-115364089-B | Application of sanggenon C in preparation of medicine for treating glioblastoma | 西南大学 | 2023-10-17 | — | — | CN | disclosed |
| US-20230190852-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-115950978-A | Method for identifying flavonol novel compound in epimedium secondary metabolic pathway | 重庆市中药研究院 | 2023-04-11 | — | — | CN | disclosed |
| CN-115364089-A | Application of sanggenon C in preparing medicine for treating glioblastoma | 西南大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-114796194-A | Application of DA adduct derived from Morus plant in preparation of beta-G inhibitor | 澳门大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-110872267-B | Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor | 复旦大学 | 2022-07-08 | — | — | CN | disclosed |
| CN-109207450-B | Flavonoid isopentenyl transferase gene and application thereof | 中国农业科学院北京畜牧兽医研究所 | 2022-04-15 | — | — | CN | disclosed |
| US-11123393-B2 | Compositions and methods for joint health | UNIGEN, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| CN-110872267-A | Compound extracted from paper mulberry and application of compound in preparation of protein tyrosine phosphatase 1B inhibitor | 复旦大学 | 2020-03-10 | — | — | CN | disclosed |
| EP-3010928-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | Unigen, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20160067296-A1 | Compositions and Methods for Joint Health | UNIGEN, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150072953-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014204866-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-6399579-B1 | SOLVENT EXTRACTION; PLANT EXTRACTS | HAUSER, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2002013842-A1 | COMPOSITIONS COMPRISING ICARISIDE I AND ANHYDROICARITIN AND METHODS FOR MAKING THE SAME | HAUSER, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072953-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | PTGES, PTGES3, PTGES2 | CYP3A4 1888/4885MEN1 3730/4885KMT2A 3613/4885 |
| US-11123393-B2 | Compositions and methods for joint health | PTGES, PTGES3, PTGES2 | CYP3A4 1888/4885MEN1 3730/4885KMT2A 3613/4885 |
| US-20160067296-A1 | Compositions and Methods for Joint Health | PTGES, PTGES3, PTGES2 | CYP3A4 1888/4885MEN1 3730/4885KMT2A 3613/4885 |
| US-20230190852-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | PTGES, PTGES3, PTGES2 | CYP3A4 1888/4885MEN1 3730/4885KMT2A 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.